

Flexion Therapeutics Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 19-Jan-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)

GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 9

 Phase 2 Clinical..... 10

 Discovery..... 20

[Return to Table of Contents](#)

Flexion Therapeutics Inc

COMPANY OVERVIEW

Company Name	Flexion Therapeutics Inc
Parent Company Name	Flexion Therapeutics Inc
Website	http://flexiontherapeutics.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	3
Number of Patents as Owner	2
Number of Patents as Third Party	0
Number of Deals	4
Key Indications	Pain,Inflammatory disease
Key Target-based Actions	Glucocorticoid agonist,TrkA receptor antagonist
Key Technologies	Small molecule therapeutic,Sustained release formulation,Intra-articular formulation,Systemic formulation unspecified,Steroid,Controlled release formulation,Matrix formulation,Emulsion formulation,Injectable formulation,Microparticle formulation

COMPANY PROFILE

SUMMARY

Flexion Therapeutics, a private US company founded in 2007, is focused on the development of therapeutics designed to target inflammatory and analgesic pathways.

LICENSING AGREEMENTS

In January 2010, Flexion licensed four undisclosed, late-stage, high-value, anti-inflammatory clinical compounds; one each from Merck Serono and AstraZeneca, and two further compounds from an undisclosed partner. The compounds would potentially be developed for inflammatory conditions, including intra-articular treatment of osteoarthritis, and tinnitus. Flexion would make milestone and royalty payments to all its partners.

In October 2009, Flexion expected to announce deals with three major pharmaceutical companies in the near future.

FINANCIAL

In December 2014, the company was to sell 3.5 million shares of common stock in an underwritten public offering. At that time, the underwriters were to be granted a 30-day option to purchase up to an additional 15% of shares; later that month, the company priced the offering of 5.04 million shares at \$17.00 per share. The additional 756,000 shares of common stock were also granted to the underwriters. At that time, the offering was expected to close on December 17, 2014; later that month, the offering was closed and a total of 5,796,000 shares of the company's common stock were sold including the 756,000 shares of common stock which were sold to the underwriters pursuant to the over-allotment option.

In January 2014, Flexion filed a registration statement on Form S-1 for a proposed initial public offering of shares of its common stock. In February 2014, the company announced the pricing of its initial public offering of 5,000,000 shares of common stock at a price of \$13 per share. Trading of shares was expected to begin on February 12, 2014, on the NASDAQ Global Market, under the ticker symbol "FLXN". The underwriters were granted a 30-day option to buy up to an additional 750,000 shares of common stock. The offering was expected to close on February 18, 2014; later that month, the offering was closed and net proceeds of \$67.3 million was expected; in March 2014, the offering was closed and the company raised gross proceeds of approximately \$75 million.

In December 2012, Flexion raised \$20 million in a series B financing round.

In January 2010, Flexion raised \$42 million from a series A financing round, from Pfizer Venture Capital group.

[Return to Table of Contents](#)




In October 2009, Flexion raised \$33 million from a series A financing round.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	3	0	3
Immune disorder	0	2	2
Neoplasm	0	2	2
Otorhinolaryngological disease	0	1	1
Gastrointestinal disease	0	1	1
Inflammatory disease	0	1	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Discovery	1
No Development Reported	3

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	1	0	1
Drug - Development/Commercialization License	0	0	3	0	3

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	1	5
Inflammatory disease	0	2
Musculoskeletal disease	0	2

[Return to Table of Contents](#)



Trials by Phase

Phase	Ongoing	All
Phase 3	1	1
Phase 2	0	4

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Neurological disease	3	0	3
Inflammatory disease	3	0	3

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

FX-005

FX-005 SNAPSHOT

Drug Name	FX-005
Key Synonyms	
Originator Company	AstraZeneca plc
Active Companies	Flexion Therapeutics Inc
Inactive Companies	AstraZeneca plc
Highest Status	Phase 2 Clinical
Active Indications	Pain
Target-based Actions	p38 MAP kinase inhibitor
Other Actions	Analgesic;Anti-inflammatory
Technologies	Small molecule therapeutic;Intra-articular formulation;Sustained release formulation
Last Change Date	04-Mar-2014

FX-005 DEVELOPMENT PROFILE

SUMMARY

Flexion, presumed to be under license from AstraZeneca, is developing a sustained-release formulation of p38 MAP kinase inhibitor FX-005, for the potential intra-articular treatment of pain in patients with osteoarthritis. In May 2012, a phase IIb dose-ranging trial was planned to begin in the first half of 2013. In December 2010, a phase I/II trial in patients with osteoarthritis of the knee was initiated. In April 2012, the trial was completed and in May 2012, top-line results were reported. In March 2013, the drug was listed as being in phase II studies.

FX-005 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Flexion Therapeutics Inc	Pain	Canada	Phase 2 Clinical	31-Dec-2010
Flexion Therapeutics Inc	Pain	Spain	Phase 2 Clinical	31-Dec-2010
AstraZeneca plc	Pain	UK	Discontinued	29-Jan-2010

[Return to Table of Contents](#)



FX-005 DRUG NAMES

Names	Type
intra-articular osteoarthritis treatment, Flexion/Merck Serono	
FX-005	Research Code

FX-005 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pain											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	1	0	0	0	0	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

FX-005 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Flexion Therapeutics Inc	0	0	1	0	1
AstraZeneca plc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

triamcinolone acetonide (pain), Flexion

triamcinolone acetonide (pain), Flexion SNAPSHOT

Drug Name	triamcinolone acetonide (pain), Flexion
Key Synonyms	triamcinolone acetonide
Originator Company	Flexion Therapeutics Inc
Active Companies	Flexion Therapeutics Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Pain
Target-based Actions	Glucocorticoid agonist
Other Actions	Analgesic;Steroidal anti-inflammatory
Technologies	Small molecule therapeutic;Intra-articular formulation;Steroid;Sustained release formulation
Last Change Date	06-Dec-2014

triamcinolone acetonide (pain), Flexion DEVELOPMENT PROFILE

SUMMARY

Flexion is developing FX-006, a sustained-release triamcinolone acetonide formulation, for the potential intra-articular treatment of pain in patients with osteoarthritis (OA) of knee . In June 2012, a phase IIa trial was initiated in patients with OA of the knee in Canada and Australia ; in December 2012, data were reported ; by April 2013, enrollment had been completed in the US, Canada, and Australia ; in June 2013, phase IIb top-line data were reported. In December 2014, a phase III trial was planned to be initiated in early 2015.

triamcinolone acetonide (pain), Flexion DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Flexion Therapeutics Inc	Pain	Australia	Phase 2 Clinical	30-Jun-2012
Flexion Therapeutics Inc	Pain	Canada	Phase 2 Clinical	30-Jun-2012
Flexion Therapeutics Inc	Pain	US	Phase 2 Clinical	18-Apr-2013

triamcinolone acetonide (pain), Flexion CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
76-25-5	1
	
Name	Type
triamcinolone acetonide	USAN
Azmacort	Trade Name
Visagen	Trade Name
Tri-Nasal	Trade Name
AllerNaze	Trade Name
MaQaid	Trade Name
CLS-1001	Research Code
CLS-1003	Research Code

triamcinolone acetonide (pain), Flexion DRUG NAMES

Names	Type
triamcinolone acetonide (pain), Flexion	
FX-006	Research Code
triamcinolone acetonide	USAN

triamcinolone acetonide (pain), Flexion CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pain											
0	0	1	1	0	3	0	0	0	0	1	4

[Return to Table of Contents](#)

Osteoarthritis											
0	0	0	0	0	2	0	0	0	0	0	2
Carpal tunnel syndrome											
0	0	0	0	0	0	0	0	1	1	1	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	1	0	3	0	0	1	1	2	5

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical



Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)



DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Flexion Therapeutics Inc	0	0	1	0	1
Southwest Research Institute (SwRI)	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Flexion Therapeutics Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1

[Return to Table of Contents](#)

FX-007

FX-007 SNAPSHOT

Drug Name	FX-007
Key Synonyms	
Originator Company	Flexion Therapeutics Inc
Active Companies	Flexion Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Pain
Target-based Actions	TrkA receptor antagonist
Other Actions	Anti-inflammatory;Analgesic
Technologies	Small molecule therapeutic;Intra-articular formulation;Sustained release formulation
Last Change Date	04-Mar-2014

FX-007 DEVELOPMENT PROFILE

SUMMARY

Flexion is investigating FX-007, a sustained-release formulation of a small-molecule TrkA receptor antagonist for the potential intra-articular treatment of refractory pain in end-stage disease/joint replacement. In June 2013, development was ongoing. In March 2013, a pre-IND meeting was to be requested and proof-of-concept bunionectomy clinical trial to be initiated in 2H 2014; data were expected in 1H 2015 .

FX-007 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Flexion Therapeutics Inc	Pain	US	Discovery	25-Oct-2011

FX-007 DRUG NAMES

Names	Type
FX-007	Research Code


[Return to Table of Contents](#)



FX-007 DEALS AND PATENTS

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
AstraZeneca plc	1	0	0	0	1
Flexion Therapeutics Inc	0	0	1	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

